In a meta-analysis (59), K-RAS mutation was associated with poorer prognosis (HR = 1.45, 95% CI: 1.29–1.62), particularly in adenocarcinoma and early-stage NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.